Non‐surgical management of erectile dysfunction

Levy, Andy; Crowley, Tessa; Gingell, Clive

doi:10.1046/j.1365-2265.2000.00954.x

Cited by 17 publications

(10 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some trials have shown the efficacy of testosterone in ED patients. 13,24,25 Dual therapy with testosterone and sildenafil may be beneficial in this group of patients. We recommend selection of patients by excluding those with contraindications to either medication.…”

Section: Discussionmentioning

confidence: 99%

A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation

Chatterjee

Wood²,

Mcgarrigle³

et al. 2004

j fam plann reprod health care

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation

Chatterjee

Wood²,

Mcgarrigle³

et al. 2004

j fam plann reprod health care

View full text Add to dashboard Cite

show abstract

“…The identification of an organic or a psychological factor in a patient with ED does not mean it is the predominant cause of his ED. While organic factors are thought to be present in the majority of ED cases, psychological aspects are often important contributing factors [2–4]. Indeed, it is likely that the majority of individuals who comprise the broad population of ED sufferers manifest underlying psychogenic in addition to organic components, irrespective of ultimate classification by the health care practitioner.…”

Section: Introductionmentioning

confidence: 99%

Vardenafil Improves Erectile Function in Men with Erectile Dysfunction Irrespective of Disease Severity and Disease Classification

Donatucci

Eardley

Buvat

et al. 2004

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Background Vardenafil (Levitra®) is a potent and selective phosphodiesterase 5 (PDE5) inhibitor used in the management of erectile dysfunction (ED). This retrospective subgroup analysis assessed the effectiveness of vardenafil treatment in men with ED of different baseline severity and disease classification. Methods Data from two pivotal, randomized, double-blind, placebo-controlled clinical trials enrolling men from the general ED population who received placebo or vardenafil 5 mg, 10 mg, or 20 mg during a 12-week treatment period were retrospectively analysed, stratifying by psychogenic, organic, and mixed ED disease classification as determined by the investigator. Efficacy endpoints included the International Index of Erectile Function (IIEF)-Erectile Function (EF) domain score, per-patient diary response rates to questions on penile insertion [Sexual Encounter Profile (SEP-2)] and maintenance of erection (SEP-3) and rates of positive response to the Global Assessment Question (GAQ). Results Data from 1,385 men who received at least one dose of study medication and had pre- and post-baseline measures of efficacy available (intent-to-treat population) are presented. At baseline 37–41% of patients had severe ED, 30–34% moderate, 22% mild-to-moderate and 6–8% mild ED. At baseline, 46–51% of patients were considered to have an organic cause for ED, 13–16% psychogenic ED, and 36–38% mixed classification of ED. For all classifications and for mild-to-moderate to severe ED, men treated with 10 or 20 mg of vardenafil showed statistically and clinically significant improvements (P < 0.001) in IIEF-EF scores, diary response rates to the SEP-2 and SEP-3 questions, and GAQ as compared with those given placebo. The greatest improvements relative to placebo were noted in patients with more severe ED. The most common treatment-emergent adverse events were headache, flushing, rhinitis, dyspepsia, and were dose-related, mostly mild to moderate in intensity and consistent with the class. Conclusion Vardenafil improves EF in men with ED irrespective of investigator-determined classification and baseline ED severity.

show abstract

“…Sildenafil therapy improves erectile dysfunction caused by both psychogenic and organic factors. [14] For male CKD patients who do not respond to Sildenafil, treatment options include intracavernous injection of alprostadil and the use of vacuum or constriction devices. [53]…”

Section: Principle Of Management Of Sexual Dysfunction In Chronic Kidmentioning

confidence: 99%

Sexual and gonadal dysfunction in chronic kidney disease: Pathophysiology

Rathi

Ramachandran

2012

Indian J Endocr Metab

View full text Add to dashboard Cite

Sexual and gonadal dysfunction/infertility are quite common in patients with chronic kidney disease. Forty percent of male and 55% of female dialysis patients do not achieve orgasm. The pathophysiology of gonadal dysfunction is multifactorial. It is usually a combination of psychological, physiological, and other comorbid factors. Erectile dysfunction in males is mainly due to arterial factors, venous leakage, psychological factors, neurogenic factors, endocrine factors, and drugs. Sexual dysfunction in females is mainly due to hormonal factors and manifests mainly as menstrual irregularities, amenorrhea, lack of vaginal lubrication, and failure to conceive. Treatment of gonadal dysfunction in chronic kidney disease is multipronged and an exact understanding of underlying pathology is essential in proper management of these patients.

show abstract

Non‐surgical management of erectile dysfunction

Cited by 17 publications

References 105 publications

A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation

A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation

Vardenafil Improves Erectile Function in Men with Erectile Dysfunction Irrespective of Disease Severity and Disease Classification

Sexual and gonadal dysfunction in chronic kidney disease: Pathophysiology

Contact Info

Product

Resources

About